Paper Details

  1. Home
  2. Paper Details

The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma.

Author: HillengassJens, HolsteinSarah A, McCarthyPhilip, MerzAlmuth Maria Anni, MerzMaximilian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review explores the role of different maintenance strategies after autologous stem cell transplantation for newly diagnosed myeloma. It highlights the benefits of lenalidomide maintenance in prolonging progression-free and overall survival, but also acknowledges the potential side effects and discusses future research directions.
Paper Details　
Original Abstract of the Article :
<b>Introduction</b>: Maintenance therapy after autologous transplantation is a standard of care in newly diagnosed myeloma. However, there is no universal answer to the question of which maintenance strategy should be pursued after ASCT? <b>Areas covered</b>: We conducted a MEDLINE search using the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14737140.2019.1674142

データ提供：米国国立医学図書館（NLM）

Navigating the Landscape of Multiple Myeloma Maintenance Therapy

The world of cancer treatment is constantly evolving, and multiple myeloma is no exception. This study delves into the ongoing debate about the optimal maintenance therapy following autologous stem cell transplantation (ASCT) in newly diagnosed myeloma. This research scrutinizes the available data from clinical trials to determine the best maintenance strategies post-ASCT.

Lenalidomide: A Promising Maintenance Option

A large meta-analysis concluded that lenalidomide significantly prolongs progression-free survival and overall survival after ASCT compared to observation or placebo. Additional trials have solidified lenalidomide's effectiveness in increasing high-quality responses. It appears that lenalidomide's benefits outweigh its potential side effects, including an increased risk of second primary malignancies.

Personalized Approaches to Maintenance Therapy

The study highlights the need for personalized approaches to maintenance therapy, considering factors like cytogenetic risk and the patient's individual circumstances. Future research will focus on combining different agents and monoclonal antibodies to optimize maintenance therapy. Additionally, the role of minimal residual disease status in guiding maintenance duration will be explored.

Dr. Camel's Conclusion

This research emphasizes the importance of continuous research and innovation in the field of multiple myeloma treatment. Just as an oasis provides sustenance and relief to weary travelers in the desert, researchers are diligently searching for the best maintenance strategies to improve the lives of patients with multiple myeloma.

Date :
  1. Date Completed 2020-03-13
  2. Date Revised 2020-03-13
Further Info :

Pubmed ID

31595807

DOI: Digital Object Identifier

10.1080/14737140.2019.1674142

Related Literature

Article Analysis
・Side Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.